Moleculin Biotech Achieves Key Enrollment Milestone in Pivotal Phase 2B/3 MIRACLE Trial, Setting Stage for Major Mid-2026 Data Readout
HOUSTON, TX, March 23, 2026 – Moleculin Biotech, Inc. (NASDAQ: MBRX), a clinical-stage pharmaceutical company focused on the development of innovative oncology drug candidates, announced a significant milestone in its pivotal MIRACLE clinical trial. The company has now enrolled the 45th subject in its Phase 2B/3 MIRACLE trial, which is evaluating Annamycin in combination with cytarabine (referred to as AnnAraC) for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (R/R AML).
Key Highlights and Details
-
Milestone Enrollment: The completion of enrollment for the first 45 subjects triggers the final preparation phase for the highly anticipated interim data analysis. This is a critical step in the MIRACLE trial’s timeline.
-
Interim Data Readout Imminent: The company is on track to unblind interim data from these 45 patients by mid-2026. This unblinding is considered a potentially defining inflection point for Moleculin, as it will provide the first substantial efficacy and safety data for AnnAraC in this difficult-to-treat patient population.
-
Potential Impact on Company and Shareholders: The upcoming interim data could be the most important data moment in the company’s history, as favorable results may significantly alter Moleculin’s valuation, partnership opportunities, and ability to raise future capital. The company explicitly describes this milestone as a “potentially defining inflection point,” highlighting its importance for shareholders and the future of the stock.
-
Data Significance:
-
The interim analysis is designed to assess both efficacy and safety. As the trial targets patients with relapsed or refractory AML—a population with limited treatment options—any positive signal from this data could be transformative for the company and for patients.
-
The company notes that the absence of cardiotoxicity seen in prior Annamycin studies remains a point of focus, subject to confirmation by ongoing and future data reviews.
-
Next Steps: Following the unblinding of interim data, Moleculin will update shareholders and the market on key results, which may provide the rationale for regulatory discussions, further investment, and potentially expedited clinical development.
Shareholder Considerations & Price Sensitivity
- Potential Share Price Catalyst: The interim data readout is a potentially high-impact event. Positive results may drive substantial appreciation in MBRX shares, while disappointing data could have the opposite effect.
- Funding Requirements: Moleculin explicitly states that additional significant financing is required to fully conduct its clinical trials. The company currently has no firm commitments for this financing. The ability to raise capital will be closely linked to the results of the interim data and is a key risk for shareholders.
- Forward-Looking Risks: The company includes standard forward-looking statements, emphasizing that actual results may differ materially from current expectations due to various risks, including those outlined in their public filings with the SEC.
Regulatory and Market Context
- Regulatory Pathway: The MIRACLE trial is a pivotal study. Favorable interim and final results could support registration and regulatory submission for AnnAraC in relapsed/refractory AML in the U.S. and potentially other markets.
- Competitive Position: Success in this trial could position Moleculin as a leader in the difficult R/R AML space, with AnnAraC potentially filling an unmet medical need.
Contact Information
For investor inquiries, Moleculin has provided the following contact:
Company Information
- Company Name: Moleculin Biotech, Inc.
- Address: 5300 Memorial Drive, Suite 950, Houston, TX 77007
- Trading Symbol: MBRX
- Exchange: NASDAQ
Disclaimer:
This article includes forward-looking statements as defined by U.S. securities laws. Actual results may differ materially from those projected due to a variety of risks and uncertainties, including but not limited to clinical trial outcomes, regulatory decisions, the company’s ability to secure additional capital, and other factors detailed in Moleculin’s filings with the Securities and Exchange Commission. This article is for informational purposes only and does not constitute investment advice. Investors should consult the company’s public filings and their own advisors before making investment decisions.
View Moleculin Biotech, Inc. Historical chart here
